Get the Stockscreener App
59.55
1.73%
1.01
After Hours:
59.71
0.16
+0.27%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $59.55, with a volume of 8.45M.
It is up +1.73% in the last 24 hours and up +0.27% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$58.54
Open:
$58.23
24h Volume:
8.45M
Relative Volume:
0.74
Market Cap:
$121.61B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
16.72
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
+4.90%
1M Performance:
+0.27%
6M Performance:
+28.76%
1Y Performance:
+26.70%
1-Day Range:
$57.83
$59.61
1-Week Range:
$56.14
$59.61
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.55 | 119.54B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,041.65 | 908.57B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
231.73 | 552.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
214.50 | 375.09B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
189.75 | 290.72B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
151.76 | 287.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - Business Wire
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid - BioPharma Dive
The Most Undervalued Healthcare Stock in the S&P 500 Right Now - The Motley Fool
Bristol Myers Squibb Partners With Anthropic to Deploy Claude Across Global Operations - Digital Health News
Why so many pharmaceutical giants want to invest billions in Houston - The Business Journals
BMS expands AI push with Anthropic partnership - The Pharma Letter
PNC Financial Services Group Inc. Sells 225,894 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Hengrui, BMS deal watershed moment for China biotech - BioWorld News
Biopharma Giant Bristol Myers Squibb Partners with Anthropic for AI Integration - GuruFocus
Anthropic And OpenAI--Building Different Competitive Advantages - Benzinga
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery - Benzinga
Bristol Myers deepens AI investment with Anthropic deal - BioPharma Dive
Anthropic signs enterprise AI deal with Bristol Myers Squibb - MobiHealthNews
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows - Fierce Pharma
Bristol Myers Squibb Expands AI Push With Anthropic’s Claude for 30,000 Employees - citybiz
Bristol Myers to deploy Anthropic’s Claude AI model to accelerate drug discovery - The News International
Exclusive | Bristol-Myers Squibb Brings Anthropic’s Claude to 30,000 of Its Staff - WSJ
Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank - The Globe and Mail
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery - Reuters
Bristol Myers Squibb partners with Anthropic to deploy Claude AI By Investing.com - Investing.com Canada
Bristol Myers, Anthropic to partner on Claude use - Breakingthenews.net
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MSN
TiNivo-2 Completion: What Bristol-Myers Squibb’s Kidney Cancer Trial Means for Investors - TipRanks
Bristol-Myers Squibb Company stock (US0897961004): oncology pipeline and US expansion keep the pharm - AD HOC NEWS
Pharma giant considers Houston for $1B manufacturing campus - InnovationMap
Resona Asset Management Co. Ltd. Sells 21,761 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law - Benzinga
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Yahoo Finance
Bristol Myers Squibb eyes $1B drug manufacturing campus in Generation Park - Community Impact | News
SCOTUS rejects Medicare drug price negotiation appeals by drugmakers - Modern Healthcare News
Bristol-Myers Squibb Company stock (US0897961004): cancer drug news and pipeline focus after earning - AD HOC NEWS
Bristol-Myers Squibb Made Its Pipeline Case at BofA. Now Comes the Proof. - TIKR.com
BMY: Bristol Myers Squibb and Hengrui Pharma Strike $15.2B Licen - GuruFocus
Pharmaceutical giant eyes Houston for $1 billion campus - Chron
MCDONALD PARTNERS LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Vestcor Inc's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Another pharma giant eyes Houston for $1B plant with hundreds of jobs possible - KHOU
Bristol Myers Squibb eyes Houston for $1B pharmaceutical plant - The Business Journals
Biopharma Collaboration: Bristol Myers Squibb Partners with Heng - GuruFocus
Bristol Myers Squibb touts pipeline gains as shareholders back board at annual meeting - MSN
Bristol Myers Squibb partners with Hengrui Pharma to develop and test drugs early in China. - Pluang
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development - Intellectia AI
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape - Oncodaily
Why is Bristol-Myers Squibb stock trading higher on Thursday? - MSN
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration - CNBC
Rx Rundown: Bristol Myers Squibb, Isomorphic Labs, Partner Therapeutics and more - Medical Marketing and Media
AustralianSuper Pty Ltd Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Strategic Advisers Fidelity Alternatives Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Sivia Capital Partners, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tempus AI Stock (TEM) Opinions on Bristol Myers Squibb Partnership Expansion - Quiver Quantitative
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):